Neurocrine Biosciences

Neurocrine Biosciences, founded in 1992, is a prominent pharmaceutical entity specializing in the research and development of advanced therapeutics for complex neurological and endocrine disorders. The company focuses on addressing significant unmet medical needs, including neuroinflammatory, neurodegenerative, and neuropsychiatric conditions such as Alzheimer's disease, depression, and various brain tumors. By leveraging sophisticated biopharmaceutical science, Neurocrine Biosciences delivers life-changing treatments that target specific biological pathways and mechanisms to improve patient outcomes. Meet Neurocrine Biosciences's team to understand the leadership driving these scientific advancements.

Operating with a workforce of 1,000 - 5,000 employees, the organization maintains a robust operational footprint dedicated to clinical innovation and drug discovery. The company is strategically positioned within the competitive pharmaceutical landscape, frequently collaborating with research institutions to accelerate the delivery of novel therapies. Learn about Neurocrine Biosciences's global headquarters for detailed information regarding their primary facility in San Diego, California, which serves as the central hub for their research, development, and corporate operations.

Neurocrine Biosciences, traded under the ticker NASDAQ: NBIX, demonstrates significant market presence with annual revenues reaching $3.4B. The company’s financial stability is supported by a history of strategic stock offerings and research grants, enabling sustained investment in its diverse therapeutic pipeline. Explore financial highlights to review the company's fiscal performance, funding history, and long-term growth trajectory within the global healthcare sector. This consistent financial performance underscores their commitment to advancing medical science and delivering value to stakeholders while addressing critical health challenges.